<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572556</url>
  </required_header>
  <id_info>
    <org_study_id>GUILHEM AMRO/AOI 2017</org_study_id>
    <nct_id>NCT03572556</nct_id>
  </id_info>
  <brief_title>Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)</brief_title>
  <acronym>TangRO</acronym>
  <official_title>Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary hemorrhagic telangiectasia (HHT) results from genetic deregulation of&#xD;
      angiogenesis. It is characterized by mucocutaneous telangiectasia responsible for recurrent&#xD;
      epistaxis affecting quality of life (anaemia, iron deficiency, social distress). More rarely,&#xD;
      HHT is complicated by the appearance of pulmonary, hepatic or cerebral arteriovenous&#xD;
      malformations that can lead to serious complications: cerebrovascular accidents, cerebral&#xD;
      abscesses, high output heart failure, and massive hemoptysis (1). The intensity of symptoms&#xD;
      increases with age but with significant individual variability, even for the same mutation in&#xD;
      the same family. Thus, while the mutations responsible for the disease have been identified,&#xD;
      the pathophysiology is not fully understood because these mutations do not explain the great&#xD;
      diversity of clinical presentations. Other factors not yet identified probably play an&#xD;
      important role. Angiogenic T cells (TANG) are a newly individualized T cell population,&#xD;
      defined by a CD4+CXCR4+CD31+ phenotype, which plays a key role in differentiating endothelial&#xD;
      progenitors (2).&#xD;
&#xD;
      In an earlier study, the investigators showed that patients with HHT had a decrease in CD4+&#xD;
      and CD8+ LT compared to a cohort of healthy subjects (3).&#xD;
&#xD;
      They hypothesize that the lymphopenia mainly involves TANG, whose quantification could make&#xD;
      it possible to assess the individual level of angiogenesis during HHT. The evaluation of the&#xD;
      TANG levels could thus make it possible to personalize HHT management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">May 3, 2020</completion_date>
  <primary_completion_date type="Actual">March 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Average monthly duration (in minutes) of epistaxis over the 3 months following inclusion</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/mm3 of circulating TANG (CD3+CXCR4+CD31+) at inclusion.</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Hereditary Hemorrhagic Telangiectasia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Hereditary hemorrhagic telangiectasia patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Matched for age (+/- 5 ans) and sex.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>5 mL dry tube to separate serum&#xD;
Two 6 mL EDTA tubes for plasma separation&#xD;
Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epistaxis charts</intervention_name>
    <description>Three monthly epistaxis charts to be completed</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        outpatient&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Person who has given consent&#xD;
&#xD;
          -  Adult&#xD;
&#xD;
          -  Person capable of understanding spoken and written French&#xD;
&#xD;
        &quot;Patient&quot; group:&#xD;
&#xD;
          -  Certain HHT (3 or 4 Curacao criteria - Appendix 2):&#xD;
&#xD;
          -  Recurring epistaxis&#xD;
&#xD;
          -  Telangiectasia of the skin or mouth&#xD;
&#xD;
          -  Family hereditary context&#xD;
&#xD;
          -  Arteriovenous visceral malformations&#xD;
&#xD;
          -  Causal mutation identified&#xD;
&#xD;
          -  Person capable of completing monthly epistaxis charts&#xD;
&#xD;
        &quot;Control&quot; group :&#xD;
&#xD;
        - Control subjects will be matched to patients for age (+/- 6 years) and sex.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person not affiliated to a national health insurance scheme&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Protected adult&#xD;
&#xD;
          -  Hemoglobin levels less than 9 g/dl in the last 15 days&#xD;
&#xD;
          -  Progressive or recent infectious disease, autoimmune disease or cancer (less than 6&#xD;
             months)&#xD;
&#xD;
          -  Immunosuppressive treatment in progress or recent (less than 6 months), including&#xD;
             systemic steroid therapy. The use of inhaled or topical steroids is not an exclusion&#xD;
             criterion.&#xD;
&#xD;
          -  Treatment in progress or stopped less than 6 months ago or to be introduced within the&#xD;
             next 3 months of the following medications:&#xD;
&#xD;
               -  bevacizumab&#xD;
&#xD;
               -  tranexamic acid&#xD;
&#xD;
               -  dipeptidyl peptidase 4 inhibitors (diabetic patient)&#xD;
&#xD;
               -  beta-blockers (hypertensive patient)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

